Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.

"CONFLICTS OF INTEREST Guarantor of the article: Kwang-Hyub Han, MD. Specific author contributions: H.J.Y. wrote the manuscript and performed the formal analysis and critical revision. K.H.H.: was involved in the study conception, design, and supervision. All the other authors contributed to data acquisition and revision of the manuscript. Financial support: This work was supported by Ildong Pharmaceutical. This sponsor had a partial role in study design, collection, analysis, and interpretation of data. Potential competing interests: K.H.H. received grants from the clinical trial Study HighlightsWHAT IS KNOWN✓ BSV is a new treatment of chronic hepatitis B virus infection.✓ BSV has an antiviral efficacy comparable with that of TDF over 48 weeks.✓ BSV has a better safety profile than TDF in terms of bone and renal outcomes.WHAT IS NEW HERE✓ BSV demonstrated durable and potent antiviral activity over 144 weeks.✓ Approximately 88% of subjects had HBV DNA <69 IU/mL without antiviral resistance mutations.✓ Long-term BSV treatment for chronic hepatitis B is safe and improves fibrosis.sponsor Ildong Pharmaceutical. All the other authors declare no conflicts of interest."

"Financial support: This work was supported by Ildong Pharmaceutical. This sponsor had a partial role in study design, collection, analysis, and interpretation of data."